Journal Scans
Weekly Docetaxel, Cisplatin, and 5-Fluorouracil as Initial Therapy for Patients With Advanced Gastric and Esophageal Cancer
Weekly DCF for Advanced Gastroesophageal Cancers
MJ Overman, SM Kazmi, J Jhamb, E Lin, JC Yao, JL Abbruzzese, L Ho, J Ajani, A Phan
20100027
2010 Jan 27
Cancer
Weekly Docetaxel, Cisplatin, and 5-Fluorouracil as Initial Therapy for Patients With Advanced Gastric and Esophageal Cancer
Cancer. 2010 Jan 27;116(6):1146-1453, MJ Overman, SM Kazmi, J Jhamb, E Lin, JC Yao, JL Abbruzzese, L Ho, J Ajani, A Phan
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Cancers of the stomach, gastroesophageal junction, and esophagus are very aggressive cancers, conferring poor 5-year overall survival (OS). Recent large, phase III trials have demonstrated that, with chemotherapy, patients who have metastatic disease achieve median survivals of only 8 to 11 months. The US Food and Drug Administration has approved the combination of docetaxel, cisplatin, and infusional 5-fluorouracil (DCF) every 3 weeks as first-line therapy for advanced gastroesophageal and gastric...
